Lead analyst view and downgrade
Morgan Stanley revised its stance on Novo Nordisk to Underweight from Equal-weight, pointing to a subdued mid-term growth outlook and specific concerns about the approaching patent cliff for semaglutide - the active ingredient behind Ozempic and Wegovy. The change was led by Thibault Boutherin and colleagues, who argued that Novo’s valuation "not entirely" captures the company’s weaker medium-term growth and "the implications of the semaglutide patent cliff on Novo’s terminal value." The bank maintained a price target of 250 Danish crowns, which it says implies more than 10% downside from the last closing price.
Market reaction
Following the announcement, Novo Nordisk shares dropped 2.6% in early trading in Copenhagen.
Growth and earnings forecasts
Morgan Stanley projects relatively modest expansion for Novo over the immediate horizon. The bank expects revenue and EBIT to rise by 2-3% in 2027, a view it describes as broadly in line with market consensus. For the period from 2027 to 2030, Morgan Stanley models a compound annual growth rate of 4% for both revenue and EBIT. These figures sit below the bank’s expectations for the broader European large pharmaceutical sector, which it forecasts to deliver 4% revenue growth and 7% EBIT growth over the same period.
Product concentration and the patent cliff
Semaglutide continues to dominate Novo’s sales mix. Morgan Stanley reports that semaglutide accounted for 75% of the company’s sales in 2026 and will face a substantial patent cliff in the early-to-mid 2030s across Europe and the United States. In the bank’s base case, semaglutide still represents 59% of sales in 2031, the year when loss-of-exclusivity (LOE) effects begin to materialize in their model.
New product expectations vs. competitive pressure
The bank models Novo’s oral obesity franchise reaching $10 billion in sales by 2031, but it cautions that this outcome "will not be enough to offset pricing and competitive headwinds." Morgan Stanley’s proprietary survey of 200 primary care physicians indicated accelerating adoption of GLP-1 therapies for diabetes and obesity, while also signaling potential market share erosion for Novo. Over the next 18 months, the survey suggests Novo could cede share to Eli Lilly’s existing GLP-1 treatments and to retatrutide, which Morgan Stanley expects to enter the market in 2027.
Valuation context
On a multiples basis, Morgan Stanley notes Novo is trading at 12.5 times its 2027 estimated earnings. That multiple is roughly a 7% discount to European large-cap pharmaceutical peers, but about a 35% premium relative to global peers facing their own LOE dynamics, including Sanofi and GSK. The analysts added that "The premium [is] more pronounced over GSK (10x) and Sanofi (8x)."
Upcoming events and management messaging
Looking ahead, Morgan Stanley said it sees "limited scope for major announcements" at Novo’s capital markets day scheduled for September 21. Management is nevertheless expected to restate its strategic vision for the oral obesity opportunity and to give updates on business development priorities, including therapeutic areas such as metabolic dysfunction-associated steatohepatitis (MASH) and chronic kidney disease.
Potential upside and key sensitivities
The analysts highlighted a clear upside scenario: if Novo’s oral obesity treatments secure a larger-than-expected patient share and show more resilience to competition and generic pricing pressure than the bank currently assumes, outcomes could be materially better than modeled. Outside of that scenario, the bank’s downgrade reflects the risk that product concentration, competition and LOE pressures will constrain Novo’s terminal valuation.
Note: The article reports Morgan Stanley’s published views, forecasts and survey findings as described above.